ClinicalTrials.gg
CompletedNCT03951805Updated Apr 5, 2021Results posted

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

A Phase 2 interventional study of Insulin icodec and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 43 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-05.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
11th of 27
205 · median 84
Started
2019
with 3 others
Phase 2
3 of 27
none open now
Registered
9th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 4 that started in 2019, is one of 3 in phase 2, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared. This is done to find the best way to change the dose of insulin 287. Participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. Which treatment participants get is decided by chance. The study will last for about 5 months (23 weeks). Participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the study doctor will ask participants to:

  • measure blood sugar every day with a blood sugar meter using a finger prick.
  • write down different information in a diary daily and return this to the study doctor.
  • wear a medical device (sensor) that measure blood sugar all the time for 18 weeks (about 4 months) during the study.

Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Male or female, aged 18-75 years (both inclusive) at the time of signing
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
  • of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory
  • Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):

    1. Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records)
    2. Free or fixed combination therapy: Metformin as outlined above plus/minus DPP4i with or without SGLT2i is allowed:

    i) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose) ii) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose )

  • Insulin-naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
  • (BMI) below or equal to 40.0 kg/m\^2
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Insulin 287 algorithm A

    Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).

    Drug: Insulin icodec

  • Experimental
    Insulin 287 algorithm B

    Controlled on metformin with or without DPP4i and with or without SGLT2i.

    Drug: Insulin icodec

  • Experimental
    Insulin 287 algorithm C

    Controlled on metformin with or without DPP4i and with or without SGLT2i.

    Drug: Insulin icodec

  • Active comparator
    Insulin Glargine algorithm D

    Controlled on metformin with or without DPP4i and with or without SGLT2i.

    Drug: Insulin Glargine

Interventions

  • Administered subcutaneously SC once weekly. Starting dose will be 70U.

    Also known as: Insulin 287

  • Administered subcutaneously SC once daily.The starting dose will be 10U.

06

What researchers measure

Primary outcomes

  1. Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)

    The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication). The endpoint is based on data recorded by CGM system. It was required that at least 70% of the planned CGM measurements during weeks 15-16 were available for endpoint data to be included in the analysis.

    Time frame: During the last 2 weeks of treatment (week 15 and 16)

Secondary outcomes

  1. Change in HbA1c (Glycated Haemoglobin)

    Estimated mean change in HbA1c from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)

  2. Change in Fasting Plasma Glucose (FPG)

    Estimated mean change in FPG from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)

  3. Change in Body Weight

    Estimated mean change in body weight from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)

  4. Weekly Insulin Dose

    Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

    Time frame: During the last 2 weeks of treatment (week 15 and 16)

  5. Number of Treatment Emergent Adverse Events (TEAEs)

    A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period was the time period from first dose of trial product (week 0, visit 2) until the follow-up visit (week 21, visit 20) or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin.

    Time frame: From baseline week 0 (visit 2) to week 21 (visit 20)

  6. Number of Severe Hypoglycaemic Episodes (Level 3)

    Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.

    Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)

  7. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.

    Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)

  8. Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)

    Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and \< 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by BG meter. Number of hypoglycaemic alert episodes (level 1) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.

    Time frame: From baseline week 0 (visit 2) to week 16 (visit 18)

07

Results

Posted Jan 8, 2021

Participant flow

The trial was conducted at 38 sites in 7 countries as follows: Croatia (4), Germany (9), Hungary (3), Poland (4), Slovakia (5), Spain (4), United States (9). In addition, 1 site in Slovakia and 3 sites in the United States screened, but didn't randomise any subjects.

Participant flow — Overall Study
MilestoneInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Started51515251
Full analysis set (fas)51515251
Safety analysis set (sas)51515251
Completed50515251
Not completed1000
Withdrew: Adverse event1000

Outcome measures

PrimaryPercentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)

The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication). The endpoint is based on data recorded by CGM system. It was required that at least 70% of the planned CGM measurements during weeks 15-16 were available for endpoint data to be included in the analysis.

Time frame:
During the last 2 weeks of treatment (week 15 and 16)
Reported as:
Least squares mean · Percentage of time
Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)
Percentage of timeInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Percentage of Time in Target Range (TIR) 3.9-10.0 Millimoles Per Liter (mmol/L) (70-180 Milligrams Per Deciliter (mg/dL) Measured Using CGM (Continuous Glucose Monitoring)76.65 ± 1.8182.97 ± 1.8080.89 ± 1.8175.89 ± 1.82
Statistical analysis
  • Insulin 287 (Titration Algorithm A) vs Insulin Glargine (Titration Algorithm D) · ANCOVA · p = 0.7675 · Treatment difference: 0.76 · 95% CI -4.28 to 5.80
  • Insulin 287 (Titration Algorithm B) vs Insulin Glargine (Titration Algorithm D) · ANCOVA · p = 0.0051 · Treatment difference: 7.08 · 95% CI 2.12 to 12.04
  • Insulin 287 (Titration Algorithm C) vs Insulin Glargine (Titration Algorithm D) · ANCOVA · p = 0.0519 · Treatment difference: 5.01 · 95% CI -0.04 to 10.05
SecondaryChange in HbA1c (Glycated Haemoglobin)

Estimated mean change in HbA1c from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
From baseline week 0 (visit 2) to week 16 (visit 18)
Reported as:
Least squares mean · Percentage point of HbA1c
Change in HbA1c (Glycated Haemoglobin)
Percentage point of HbA1cInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Change in HbA1c (Glycated Haemoglobin)-1.00 ± 0.08-1.22 ± 0.08-1.38 ± 0.08-1.02 ± 0.08
SecondaryChange in Fasting Plasma Glucose (FPG)

Estimated mean change in FPG from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
From baseline week 0 (visit 2) to week 16 (visit 18)
Reported as:
Least squares mean · Millimoles per liter (mmol/L)
Change in Fasting Plasma Glucose (FPG)
Millimoles per liter (mmol/L)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Change in Fasting Plasma Glucose (FPG)-2.23 ± 0.17-2.42 ± 0.17-3.01 ± 0.17-2.34 ± 0.17
SecondaryChange in Body Weight

Estimated mean change in body weight from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
From baseline week 0 (visit 2) to week 16 (visit 18)
Reported as:
Least squares mean · Kilogram (Kg)
Change in Body Weight
Kilogram (Kg)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Change in Body Weight0.87 ± 0.351.11 ± 0.351.25 ± 0.350.63 ± 0.35
SecondaryWeekly Insulin Dose

Estimated mean average weekly insulin dose during the last 2 weeks of treatment is presented. The endpoint was evaluated based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was considered exposed to trial product, excluding any period after initiation of a non-randomised insulin treatment (rescue medication).

Time frame:
During the last 2 weeks of treatment (week 15 and 16)
Reported as:
Least squares mean · Units of insulin (U)
Weekly Insulin Dose
Units of insulin (U)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Weekly Insulin Dose142.47 (119.78 to 169.45)176.38 (148.30 to 209.78)208.90 (175.94 to 248.04)145.56 (122.38 to 173.12)
SecondaryNumber of Treatment Emergent Adverse Events (TEAEs)

A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. The on-treatment observation period was the time period from first dose of trial product (week 0, visit 2) until the follow-up visit (week 21, visit 20) or the last date on trial product + 5 weeks for once daily insulin and +6 weeks for once weekly insulin.

Time frame:
From baseline week 0 (visit 2) to week 21 (visit 20)
Reported as:
Number · Count of events
Number of Treatment Emergent Adverse Events (TEAEs)
Count of eventsInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Number of Treatment Emergent Adverse Events (TEAEs)44675845
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of severe hypoglycaemic episodes that occurred from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.

Time frame:
From baseline week 0 (visit 2) to week 16 (visit 18)
Reported as:
Number · Count of events
Number of Severe Hypoglycaemic Episodes (Level 3)
Count of eventsInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Number of Severe Hypoglycaemic Episodes (Level 3)0000
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3)

Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.

Time frame:
From baseline week 0 (visit 2) to week 16 (visit 18)
Reported as:
Number · Count of events
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3)
Count of eventsInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0 mmol/L (54 Milligrams Per Deciliter [mg/dL]), Confirmed by Blood Glucose (BG) Meter) or Severe Hypoglycaemic Episodes (Level 3)1280
SecondaryNumber of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)

Hypoglycaemia alert value (level 1) was defined as episodes that were sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy with plasma glucose value of equal to or above (\>=) 3.0 and \< 3.9 mmol/L (\>= 54 and \< 70 mg/dL) confirmed by BG meter. Number of hypoglycaemic alert episodes (level 1) that occured from baseline (week 0, visit 2) to end of treatment (week 16, visit 18) are presented.

Time frame:
From baseline week 0 (visit 2) to week 16 (visit 18)
Reported as:
Number · Count of events
Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)
Count of eventsInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Number of Hypoglycaemic Alert Episodes (Level 1) (Greater Than or Equal to 3.0 and Below 3.9 mmol/L (Greater Than or Equal to 54 and Below 70 mg/dL), Confirmed by Blood Glucose (BG) Meter)142011010

Adverse events

Collected over From baseline (week 0) to week 21 Results are based on the safety analysis set which included all participants exposed to at least one dose of trial product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin 287 (Titration Algorithm A)0/51 (0%)3/51 (5.9%)9/51 (17.6%)
Insulin 287 (Titration Algorithm B)0/51 (0%)1/51 (2%)10/51 (19.6%)
Insulin 287 (Titration Algorithm C)0/52 (0%)0/52 (0%)7/52 (13.5%)
Insulin Glargine (Titration Algorithm D)0/51 (0%)2/51 (3.9%)9/51 (17.6%)
Most frequent serious events
Most frequent serious events
EventInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
Angina pectorisCardiac disorders1/510/510/520/51
Choroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/510/520/51
ErysipelasInfections and infestations0/511/510/520/51
Knee arthroplastySurgical and medical procedures0/510/510/521/51
MetastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/510/520/51
PneumoniaInfections and infestations0/510/510/521/51
Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/510/510/520/51
Most frequent other events
Most frequent other events
EventInsulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)
NasopharyngitisInfections and infestations5/517/512/526/51
Back painMusculoskeletal and connective tissue disorders5/512/511/521/51
HeadacheNervous system disorders0/513/515/522/51

Baseline characteristics

The full analysis set included all randomised participants.

Age, Continuous
Age, Continuous(years)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)Total
Mean59.8 ± 9.161.2 ± 8.061.4 ± 8.060.2 ± 8.160.7 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)Total
Female2423242495
Male27282827110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)Total
Hispanic or Latino252312
Not Hispanic or Latino49465048193
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Insulin 287 (Titration Algorithm A)Insulin 287 (Titration Algorithm B)Insulin 287 (Titration Algorithm C)Insulin Glargine (Titration Algorithm D)Total
American Indian or Alaska Native00011
Asian02002
Black or African American00112
Native Hawaiian or other Pacific Islander00011
White51495147198
other00011
08

Study locations

43 sites
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Lancaster, California 93534, United States
  • Novo Nordisk Investigational Site
    Roswell, Georgia 30076, United States
  • Novo Nordisk Investigational Site
    Statesboro, Georgia 30461, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    West Seneca, New York 14224, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37411, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Austin, Texas 78731, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75231, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-9302, United States
  • Novo Nordisk Investigational Site
    Schertz, Texas 78154, United States
  • Novo Nordisk Investigational Site
    Karlovac, 47000, Croatia
  • Novo Nordisk Investigational Site
    Osijek, 31 000, Croatia
  • Novo Nordisk Investigational Site
    Rijeka, 51 000, Croatia
  • Novo Nordisk Investigational Site
    Varazdin, 42 000, Croatia
  • Novo Nordisk Investigational Site
    Bad Mergentheim, 97980, Germany
  • Novo Nordisk Investigational Site
    Essen, 45136, Germany
  • Novo Nordisk Investigational Site
    Falkensee, 14612, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Münster, 48145, Germany
  • Novo Nordisk Investigational Site
    Oldenburg I. Holst, 23758, Germany
  • Novo Nordisk Investigational Site
    Pohlheim, 35415, Germany
  • Novo Nordisk Investigational Site
    Saint Ingbert-Oberwürzbach, 66386, Germany
  • Novo Nordisk Investigational Site
    Kaposvár, 7400, Hungary
  • Novo Nordisk Investigational Site
    Szeged, H-6725, Hungary
  • Novo Nordisk Investigational Site
    Zalaegerszeg, 8900, Hungary
  • Novo Nordisk Investigational Site
    Bialystok, 15-435, Poland
  • Novo Nordisk Investigational Site
    Lublin, 20-538, Poland
  • Novo Nordisk Investigational Site
    Radom, 26-600, Poland
  • Novo Nordisk Investigational Site
    Tomaszow Mazowiecki, 97-200, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 02-507, Poland
  • Novo Nordisk Investigational Site
    Banska Bystrica, 97401, Slovakia
  • Novo Nordisk Investigational Site
    Kosice, 040 01, Slovakia
  • Novo Nordisk Investigational Site
    Nitra, 94911, Slovakia
  • Novo Nordisk Investigational Site
    Rimavska Sobota, 97901, Slovakia
  • Novo Nordisk Investigational Site
    Roznava, 04801, Slovakia
  • Novo Nordisk Investigational Site
    Velky Meder, 93201, Slovakia
  • Novo Nordisk Investigational Site
    Baracaldo, 48903, Spain
  • Novo Nordisk Investigational Site
    La Coruña, 15006, Spain
  • Novo Nordisk Investigational Site
    La Roca del Vallés, 08430, Spain
  • Novo Nordisk Investigational Site
    Vic (Barcelona), 08500, Spain
09

References and documents

Publications

  • Lingvay I, Buse JB, Franek E, Hansen MV, Koefoed MM, Mathieu C, Pettus J, Stachlewska K, Rosenstock J. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care. 2021 Jul;44(7):1595-1603. doi: 10.2337/dc20-2878. Epub 2021 Apr 19. PubMed 33875484 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Dec 2019, 7 months.

Results were first posted in Jan 2021, 1 year after primary completion.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2019
First posted
May 15, 2019
StartActual
May 9, 2019
Primary completionActual
Dec 12, 2019
CompletionActual
Jan 17, 2020
Results first posted
Jan 8, 2021
Last update
Apr 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03951805
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 15, 2019
Start date
May 9, 2019
Primary completion
Dec 12, 2019
Completion
Jan 17, 2020
Results posted
Jan 8, 2021
Last update
Apr 5, 2021

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion